HER2‐positive breast cancer patients have seen significantly improved survival rates compared to those with TNBC, primarily due to the inclusion of effective anti‐HER2 treatments in adjuvant therapy [2, 22]. This evidence concerns the gene ERBB2 and breast carcinoma.